Endo Pharmaceuticals Holdings Inc.’s said on Monday that it would discontinue development of its pain drug MorphiDex due to poor study results. The firm announced that the investigational product failed to meet the primary and secondary endpoints in a second phase III study.
The company was advancing MorphiDex, a combination of morphine and the N-methyl-D-aspartate (NMDA)-receptor antagonist, dextromethorphan, to treat chronic pain. The results disclosed on Monday involved a phase III trial that compared MorphiDex with immediate-release morphine sulfate in 327 patients.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!